KYMR
Kymera Therapeutics Inc

726
Mkt Cap
$4.66B
Volume
648,464.00
52W High
$68.46
52W Low
$19.45
PE Ratio
-18.02
KYMR Fundamentals
Price
$64.63
Prev Close
$64.82
Open
$66.08
50D MA
$57.56
Beta
1.67
Avg. Volume
636,834.17
EPS (Annual)
-$2.98
P/B
4.91
Rev/Employee
$250,382.98
Loading...
Loading...
News
all
press releases
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-two ratings firms that are presently covering the stock, Marketbeat...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High - Still a Buy?
Kymera Therapeutics (NASDAQ:KYMR) Hits New 12-Month High - Should You Buy...
MarketBeat·2d ago
News Placeholder
Candriam S.C.A. Invests $6.73 Million in Kymera Therapeutics, Inc. $KYMR
Candriam S.C.A. acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange...
MarketBeat·5d ago
News Placeholder
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High - Here's What Happened
Kymera Therapeutics (NASDAQ:KYMR) Hits New 1-Year High - What's Next...
MarketBeat·8d ago
News Placeholder
B. Riley Predicts Stronger Earnings for Kymera Therapeutics
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at B. Riley lifted their FY2025 earnings per share estimates for Kymera Therapeutics in a research note issued to investors on...
MarketBeat·12d ago
News Placeholder
KYMR FY2025 EPS Raised by Brookline Capital Management
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at Brookline Capital Management raised their FY2025 earnings estimates for shares of Kymera Therapeutics in a report issued on...
MarketBeat·12d ago
News Placeholder
What is HC Wainwright's Forecast for KYMR FY2025 Earnings?
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at HC Wainwright cut their FY2025 earnings estimates for shares of Kymera Therapeutics in a research report issued on...
MarketBeat·12d ago
News Placeholder
Equities Analysts Set Expectations for KYMR FY2025 Earnings
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for Kymera Therapeutics in a research note issued to investors on...
MarketBeat·12d ago
News Placeholder
Wells Fargo & Company Forecasts Strong Price Appreciation for Kymera Therapeutics (NASDAQ:KYMR) Stock
Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $53.00 to $69.00 and gave the company an "overweight" rating in a research report on Wednesday...
MarketBeat·14d ago
News Placeholder
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago

Latest KYMR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.